Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis

Status Recruiting

Clinical Trial Summary

To evaluate the safety and efficacy of liposomal amphotericin B and amphotericin B deoxycholate with or without flucytosine followed by fluconazole for the treatment of cryptococcal meningitis.

Clinical Trial Description

Subjects who meet all eligible requirements will be randomized into study group （Lipo-AB）or control group（Amphotericin B deoxycholate） in 2:1 ratio. Subjects will be treated with induction therapy in study group or in control group with flucytosine for at least 14 days, and followed by consolidation therapy for another 56 days after CSF sterilization. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02136030
Study type	Interventional
Source	TTY Biopharm
Contact	Yee-chun Chen, MD
Phone	886-2-2312-3456
Email	yeechunchen@gmail.com
Status	Recruiting
Phase	N/A
Start date	February 2011
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01589289` - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC	Phase 3
Completed	`NCT00976040` - Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis	Phase 4
Completed	`NCT04031833` - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)	Phase 1/Phase 2
Completed	`NCT00830856` - Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa	N/A
Completed	`NCT04532463` - Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
Completed	`NCT02098525` - Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy	N/A
Completed	`NCT01075152` - Cryptococcal Optimal ART Timing Trial	Phase 4
Active, not recruiting	`NCT01715922` - Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa	Phase 2/Phase 3
Completed	`NCT00145249` - Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis	Phase 2
Completed	`NCT01802385` - Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis	Phase 3
Terminated	`NCT00324025` - Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS	Phase 2
Completed	`NCT02955862` - Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report	Phase 1
Recruiting	`NCT03945448` - Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia	Phase 2/Phase 3
Active, not recruiting	`NCT02624453` - Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS	N/A
Recruiting	`NCT00867269` - Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Completed	`NCT01535469` - Operational Research for Cryptococcal Antigen Screening	Phase 4
Active, not recruiting	`NCT04072640` - Three Induction Treatments on Cryptococcal Meningitis	Early Phase 1
Not yet recruiting	`NCT05541107` - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3	Phase 3
Not yet recruiting	`NCT02686853` - Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis	Phase 4
Not yet recruiting	`NCT04140461` - AmB Dose for Cryptococcal Meningitis	Phase 3